Irritable Bowel Syndrome and the Small Intestinal Microflora. What We Do Know?

1. ZAMAN A. Irritable bowel syndrome. Clin Cornerstone. 2002; 4:22-33.10.1016/S1098-3597(02)90003-7Search in Google Scholar

2. BRANDT LJ, CHEY WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl. 1:S1.10.1038/ajg.2009.134Search in Google Scholar

3. DROSSMAN DA, LI Z, ANDRUZZI E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.10.1007/BF01303162Search in Google Scholar

4. HAHN BA, SAUNDERS WB, MAIER WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997; 42:2585.10.1023/A:1018889318063Search in Google Scholar

5. SAITO YA, LOCKE GR, TALLEY NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816.10.1111/j.1572-0241.2000.03192.xSearch in Google Scholar

6. TALLEY NJ, ZINSMEISTER AR, VAN DYKE C, MELTON LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927.10.1016/0016-5085(91)90717-YSearch in Google Scholar

7. THOMPSON WG, IRVINE EJ, PARE P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47:225.10.1023/A:1013208713670Search in Google Scholar

8. HUNGIN AP, WHORWELL PJ, TACK J, MEARIN F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment PharmacolTher 2003; 17:643.10.1046/j.1365-2036.2003.01456.x12641512Search in Google Scholar

9. DROSSMAN DA. Rome III: the new criteria. Chin J Dig Dis. 2006; 7(4):181-5.10.1111/j.1443-9573.2006.00265.x17054578Search in Google Scholar

10. DONALDSON RM, JR. Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med. 1964;270:1050-1056.10.1056/NEJM19640514270200714122803Search in Google Scholar

11. FORD AC, SPIEGEL BM, TALLEY NJ, MOAYYEDI P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. ClinGastroenterolHepatol.2009;7:1279-1286.10.1016/j.cgh.2009.06.03119602448Search in Google Scholar

12. BONFRATE L, TACK J, GRATTAGLIANO I, CUOMO R, PORTINCASA P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol.2013; 48(9):995-1009.10.3109/00365521.2013.79922023964766Search in Google Scholar

13. PYLERIS E, GIAMARELLOS-BOURBOULIS EJ, TZIAVRAS D, KOUSSOULAS V, BARBATZAS C, PIMENTEL M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci.2012; 57(5):1321-9.10.1007/s10620-012-2033-722262197Search in Google Scholar

14. SEKIROV I, RUSSELL SL, CAETANO M ANTUNES L, FINLAY BB. Gut microbiota in health and disease. Physiological Reviews.2010;90(3):859-904.10.1152/physrev.00045.200920664075Search in Google Scholar

15. PONNUSAMY K, CHOI JN, KIM J, LEE S-Y, LEE CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. Journal of Medical Microbiology 2011;60(6):817-827.10.1099/jmm.0.028126-0316792321330412Search in Google Scholar

16. KANG NL, OH YL. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.World J Gastroenterol. Jul 21, 2014; 20(27): 8886-8897.Search in Google Scholar

17. CARRARA M, DESIDERI S, AZZURRO M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. European Review for Medical and Pharmacological Sciences. 2008; 12(3):197-202.Search in Google Scholar

18. MALINEN E, RINTTILÄ T, KAJANDER K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. American Journal of Gastroenterology, 2005; 100(2):373-38.10.1111/j.1572-0241.2005.40312.x15667495Search in Google Scholar

19. CHOW J, LEE SM, SHEN Y, KHOSRAVI A, MAZMANIAN SK. Host-bacterial symbiosis in health and disease. Advances in Immunology.2010; 107(C):243-274.10.1016/B978-0-12-381300-8.00008-3315248821034976Search in Google Scholar

20. POSSERUD I, STOTZER PO, BJÖRNSSON ES, ABRAHAMSSON H, SIMRÉN M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007; 56(6):802-808.10.1136/gut.2006.108712195487317148502Search in Google Scholar

21. TOSKES PP. Bacterial overgrowth of the gastrointestinal tract. Adv Int Med. 1993; 38:387-407.Search in Google Scholar

22. VANNER S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut 2008; 57:1315-1321.10.1136/gut.2007.13362918250127Search in Google Scholar

23. GHOSHAL UC, SRIVASTAVA D, GHOSHAL U, MISRA A. Breath tests in the diagnosis of small intestinal bacterial over growth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J GastroenterolHepatol. 2014 Jul; 26(7):753-60.10.1097/MEG.000000000000012224849768Search in Google Scholar

24. NEWCOMER AD, MCGILL DB, THOMAS PJ, HOFMANN AF. Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med. 1975;293:1232-1236.10.1056/NEJM197512112932405Search in Google Scholar

25. URITA Y, ISHIHARA S, AKIMOTO T, KATO H, HARA N, HONDA Y, NAGAI Y, NAKANISHI K, SHIMADA N, SUGIMOTO M, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol.2006; 12:3092-3095.10.3748/wjg.v12.i19.3092Search in Google Scholar

26. PERMAN JA, MODLER S, BARR RG, ROSENTHAL P. Fasting breath hydrogen concentration: normal values and clinical application. Gastroenterology. 1984; 87:1358-1363.10.1016/0016-5085(84)90204-XSearch in Google Scholar

27. PIMENTEL M, CHOW EJ, LIN HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506.10.1111/j.1572-0241.2000.03368.xSearch in Google Scholar

28. GHOSHAL UC, GHOSHAL U, DAS K, MISRA A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006;25:6-10.Search in Google Scholar

29. BOND JH, LEVITT MD. Use of breath hydrogen (H2) to quantitate small bowel transit time following partial gastrectomy. J Lab Clin Med. 1977; 90:30-36.Search in Google Scholar

30. KING TS, ELIA M, HUNTER JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet.1998; 352:1187-1189.10.1016/S0140-6736(98)02146-1Search in Google Scholar

31. GHOSHAL UC. How to Interpret Hydrogen Breath Tests. Neurogastroenterol Motil. Jul 2011; 17(3): 312-317.10.5056/jnm.2011.17.3.312315506921860825Search in Google Scholar

32. PIMENTEL M, CHOW EJ, LIN HC. Normalization of lactulose breathtesting correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol.2003; 98:412-419.Search in Google Scholar

33. SCARPELLINI E1, GIORGIO V, GABRIELLI M, FILONI S, VITALE G, TORTORA A, OJETTI V, GIGANTE G, FUNDARÒ C, GASBARRINI A. Rifaximin treatment for small intestinalbacterialovergrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013 May; 17(10):1314-20.Search in Google Scholar

34. YAKOOB J, ABBAS Z, KHAN R, HAMID S, AWAN S, JAFRI W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011; 17:371-375.10.4103/1319-3767.87176322110922064333Search in Google Scholar

35. MEYRAT P, SAFRONEEVA E, SCHOEPFER AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment PharmacolTher. 2012; 36:1084-1093.10.1111/apt.1208723066911Search in Google Scholar

36. LUPASCU A, GABRIELLI M, LAURITANO EC, SCARPELLINI E, SANTOLIQUIDO A, CAMMAROTA G, FLORE R, TONDI P, POLA P, GASBARRINI G, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005; 22:1157-1160.10.1111/j.1365-2036.2005.02690.x16305730Search in Google Scholar

37. REDDYMASU SC, SOSTARICH S, MCCALLUM EW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010; 10:23.Search in Google Scholar

38. MORARU IG, MORARU AG, MIHAI A, CIORTESCU I, DRUG V, PORR P, VOIOSU R, IORDACHE T, DICULESCU M, PORTINCASA P, DUMITRASCU DL. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. Rom J Intern Med. 2014, 52 (4). .Search in Google Scholar

39. HUSEBYE E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy.2005; 51(suppl 1):1-22.10.1159/00008198815855746Search in Google Scholar

40. PISTIKI A, GALANI I, PYLERIS E, BARBATZAS C, PIMENTEL M, GIAMARELLOS-BOURBOULIS EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014 Jan 6.pii: S0924-8579(13)00412-3.Search in Google Scholar

41. MAGNUS S, GIOVANNI B, HARRY JF, BRENNAN MRS, ROBIN CS, STEPHEN V. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. Jan 2013; 62(1): 159-176. Search in Google Scholar